Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic/Pharmacodynamic Equivalence of MSB11455 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who provide signed and dated written informed consent~* Other protocol defined inclusion criteria could apply~Exclusion Criteria:~* Subjects who have no known hypersensitivity to any component of Neulasta or MSB11455, and laboratory test results within predefined ranges~* Other protocol defined exclusion criteria could apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- First MSB11455 Then Neulasta (Type: EXPERIMENTAL): None
- First Neulasta Then MSB11455 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).